ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ASCO 2022
03:59

ecancer

Lecture Summary - ASCO 2022 Sacituzumab Govitecan Provides Clinically Meaningful PFS Benefit for HR+/HER2- mBC

FEATURING Hope Rugo
  • 13 views
  • June 29, 2022
21:43

ecancer

ASCO 2022 on the Latest Developments in mHSPC and mCRPC

FEATURING Heather Payne, Kim Chi, Kurt Miller, Laura-Maria Krabbe
  • 238 views
  • June 28, 2022
  • 1
10:12

ecancer

ASCO 2022: ASCO and WHO to Collaborate on Quality Indicators for Cancer Facilities

FEATURING André Ilbawi
  • 10 views
  • June 27, 2022
05:50

ecancer

ASCO 2022 on the rEECur Trial: High-Dose Ifosfamide as a SoC for Recurrent and Primary Refractory Ewing Sarcoma

FEATURING Martin Mccabe
  • 28 views
  • June 24, 2022
06:54

ecancer

ASCO 2022: Head & Neck Cancer Highlights

FEATURING Mark Persky
  • 77 views
  • June 24, 2022
07:33

ecancer

ASCO 2022: Dabrafenib + Trametinib Significantly Increases Overall Response Rate in Pediatric Low-Grade Gliomas

FEATURING Eric Bouffet
  • 69 views
  • June 24, 2022
  • 1
28:07

ecancer

ASCO 2022: Latest Updates in Prostate Cancer, Including PARPi

FEATURING Eleni Efstathiou, Cora Sternberg, Neal Shore, Phil Cornford
  • 534 views
  • June 23, 2022
  • 1
08:05

ecancer

ASCO 2022 ctDNA Analyses of the Phase III VOYAGER Trial: KIT Mutational Landscape and Outcomes in Patients With Advanced GIST

FEATURING César Serrano
  • 41 views
  • June 23, 2022
05:57

ecancer

ASCO 2022 on E2211 Trial for Advanced Pancreatic Neuroendocrine Tumors: Capecitabine + Temozolomide Gives Longer PFS Than Temozolomide Alone

FEATURING Pamela Kunz
  • 60 views
  • June 23, 2022
21:40

ecancer

ASCO 2022 Panel Discussion on Current Strategies and Trials on Bladder Preservation

FEATURING Petros Grivas, Robert Jones, Phil Cornford, Kurt Miller
  • 139 views
  • June 23, 2022
04:07

ecancer

ASCO 2022: Single-Agent PD-1 Blockade as Curative-Intent Treatment in dMMR Locally Advanced Rectal Cancer

FEATURING Andrea Cercek
  • 64 views
  • June 23, 2022
06:00

ecancer

ASCO 2022 on a Phase II S1800A Trial: Ramucirumab + Pembrolizumab Improves OS in Advanced NSCLC

FEATURING Roy Herbst
  • 75 views
  • June 23, 2022
20:12

ecancer

ASCO 2022 on the Latest Updates in EGFR+ NSCLC

FEATURING Benjamin Besse, Anna Minchom, Antonio Passaro, Enriqueta Felip
  • 152 views
  • June 23, 2022
03:17

ecancer

ASCO 2022: N-803 + BCG Combination Shows Promising Results in BCG-Unresponsive NMIBC

FEATURING Karim Chamie
  • 92 views
  • June 23, 2022
06:32

ecancer

Primary Results of the Phase III SHINE Study: Ibrutinib in Combination With Bendamustine, Rituximab & Rituximab Maintenance as 1L Therapy for Older Patients With Mantle Cell Lymphoma

FEATURING Michael Wang
  • 525 views
  • June 23, 2022
  • 1
05:00

ecancer

ASCO 2022 on the Adjuvant Endocrine Therapy for ER+/HER2- Breast Cancer

FEATURING Etienne Brain
  • 120 views
  • June 23, 2022
07:14

ecancer

ASCO 2022 Sacituzumab Govitecan Provides Clinically Meaningful PFS Benefit for HR+/HER2- mBC

FEATURING Hope Rugo
  • 795 views
  • June 23, 2022
  • 5
07:25

ecancer

Updated Data From the Phase 1/2 MajesTEC-1 Study: Evaluating Teclistamab in R/R MM

FEATURING Ajay Nooka
  • 1,170 views
  • June 23, 2022
  • 2
06:05

ecancer

ASCO 2022 LUMINA Study Updates: Biomarker Guidance Allows Patients 55 or Older With Low-Grade Luminal A-Type Breast Cancer to Avoid Radiation Therapy

FEATURING Timothy Whelan
  • 829 views
  • June 23, 2022
  • 8
06:17

ecancer

ASCO 2022 Phase III EVEREST Study Updates: Everolimus After Surgery Can Improve Outcomes in Those With High-Risk RCC

FEATURING Christopher Ryan
  • 65 views
  • June 21, 2022
05:33

ecancer

ASCO 2022 ctDNA Analysis Can Help Identify the Need for Adjuvant Therapy in Stage II Colon Cancer

FEATURING Jeanne Tie
  • 103 views
  • June 21, 2022
03:36

ecancer

ASCO 2022 Panitumumab + mFOLFOX6 Improves OS for RAS Wild-Type Left-Sided mCRC

FEATURING Takayuki Yoshino
  • 74 views
  • June 20, 2022
12:04

ecancer

ASCO 2022: Breast Cancer Highlights

FEATURING Matteo Lambertini
  • 37 views
  • June 17, 2022
01:57

ecancer

Lecture Summary - ASCO 2022 CheckMate 9ER: aRCC pts on Nivolumab + Cabozantinib Achieved Deeper Responses vs Sunitinib

FEATURING Cristina Suárez
  • 13 views
  • June 17, 2022
04:05

ecancer

ASCO 2022 Momelotinib Superior to Danazol in Symptomatic and Anaemic MF Pts Previously Treated With a JAKi

FEATURING Ruben Mesa
  • 139 views
  • June 17, 2022
  • 1
03:54

ecancer

ASCO 2022 Biomarker Analysis of the NeoALTTO Trial Provides Oncofertility Insight for Younger Breast Cancer Pts

FEATURING Matteo Lambertini
  • 10 views
  • June 17, 2022
09:52

ecancer

ASCO 2022 ATHENA–MONO Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer

FEATURING Bradley Monk
  • 126 views
  • June 17, 2022
05:57

ecancer

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan vs. Treatment of Physician’s Choice in Pts With HER2-Low Unresectable/Metastatic BC

FEATURING Shanu Modi
  • 218 views
  • June 17, 2022
  • 1
05:41

ecancer

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MBC With Low HER2 Expression

FEATURING Shanu Modi
  • 37 views
  • June 17, 2022